Stem Cells Technologies

stemcellstechnologies.com

We're an innovative, digitally oriented global stem cells technology company whose reach is rapidly expanding. Our mission is to bank cells and personalize medicine for customers around the globe.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

FUJIFILM DIOSYNTH BIOTECHNOLOGIES ENTERS STRATEGIC PARTNERSHIP WITH OXGENE™ TO ADDRESS SUPPLY BOTTLENECKS IN GENE THERAPY DEVELOPMENT & MANUFACTURING

FUJIFILM Diosynth Biotechnologies | April 23, 2020

news image

FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies, announced a strategic partnership with OXGENE™, an industry leader in the design and development of gene therapy technologies. This partnership will enable FDB to deliver gene therapy products to clients with an approximate 25% le...

Read More

INTERNATIONAL BIOTECHNOLOGY LOOKING TO THE LONG TERM RATHER THAN CORONA CURES

Investors Chronicle | April 30, 2020

news image

Healthcare companies around the world are scrambling to produce drugs and vaccines to treat and immunise people against Covid-19. However, the managers of International Biotechnology Trust (IBT) are not necessarily investing in these companies as their share prices are volatile, shooting up on reports of possible treatments in development.For example, Carl Harald Janson, lead manager of International Biotechnology Trust, recently reduced the trust’s holding in Gilead Sciences (US:GIL...

Read More

Medical

MOGRIFY ANNOUNCES EXPLORATORY RESEARCH COLLABORATION WITH MRC LABORATORY OF MOLECULAR BIOLOGY

Mogrify | January 11, 2021

news image

Mogrify Limited (Mogrify®), a UK organization expecting to change the advancement of ex vivo cell therapies and pioneer the field of in vivo reconstructing treatments, and the MRC Laboratory of Molecular Biology (LMB), a top notch research lab committed to understanding significant natural cycles at the sub-atomic level, today reported an exploratory examination cooperation. The venture intends to create novel protein articulation frameworks by utilizing late advances in direct cell reconstr...

Read More

Cell and Gene Therapy

MEKONOS RAISES $4.6M FINANCING ROUND FOR TARGETED EX VIVO GENE ENGINEERING

Mekonos | November 24, 2020

news image

Mekonos, a biotech organization launching the first-of-its kind system-on-a-chip (SoC) for focused ex vivo gene engineering, today reported it has finished a $4.6 million financing round. Mekonos will utilize the new funding to quicken the SoC stage for its current and new ad organizations. The SoC stage, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The stage is versatile over all cell types and has demonstrated to ...

Read More
news image

FUJIFILM DIOSYNTH BIOTECHNOLOGIES ENTERS STRATEGIC PARTNERSHIP WITH OXGENE™ TO ADDRESS SUPPLY BOTTLENECKS IN GENE THERAPY DEVELOPMENT & MANUFACTURING

FUJIFILM Diosynth Biotechnologies | April 23, 2020

FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies, announced a strategic partnership with OXGENE™, an industry leader in the design and development of gene therapy technologies. This partnership will enable FDB to deliver gene therapy products to clients with an approximate 25% le...

Read More
news image

INTERNATIONAL BIOTECHNOLOGY LOOKING TO THE LONG TERM RATHER THAN CORONA CURES

Investors Chronicle | April 30, 2020

Healthcare companies around the world are scrambling to produce drugs and vaccines to treat and immunise people against Covid-19. However, the managers of International Biotechnology Trust (IBT) are not necessarily investing in these companies as their share prices are volatile, shooting up on reports of possible treatments in development.For example, Carl Harald Janson, lead manager of International Biotechnology Trust, recently reduced the trust’s holding in Gilead Sciences (US:GIL...

Read More
news image

Medical

MOGRIFY ANNOUNCES EXPLORATORY RESEARCH COLLABORATION WITH MRC LABORATORY OF MOLECULAR BIOLOGY

Mogrify | January 11, 2021

Mogrify Limited (Mogrify®), a UK organization expecting to change the advancement of ex vivo cell therapies and pioneer the field of in vivo reconstructing treatments, and the MRC Laboratory of Molecular Biology (LMB), a top notch research lab committed to understanding significant natural cycles at the sub-atomic level, today reported an exploratory examination cooperation. The venture intends to create novel protein articulation frameworks by utilizing late advances in direct cell reconstr...

Read More
news image

Cell and Gene Therapy

MEKONOS RAISES $4.6M FINANCING ROUND FOR TARGETED EX VIVO GENE ENGINEERING

Mekonos | November 24, 2020

Mekonos, a biotech organization launching the first-of-its kind system-on-a-chip (SoC) for focused ex vivo gene engineering, today reported it has finished a $4.6 million financing round. Mekonos will utilize the new funding to quicken the SoC stage for its current and new ad organizations. The SoC stage, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The stage is versatile over all cell types and has demonstrated to ...

Read More